Racial differences in CD8+ T cell infiltration in breast tumors from Black and White women

Yara Abdou1, Kristopher Attwood2, Ting-Yuan David Cheng3, Song Yao4, Elisa V. Bandera5,6, Gary R. Zirpoli7, Rochelle Payne Ondracek4, Leighton Stein8, Wiam Bshara8, Thaer Khoury8, Christine B. Ambrosone4 and Angela R. Omilian4*

Abstract

Background: African American/Black women with breast cancer have poorer survival than White women, and this disparity persists even after adjusting for non-biological factors. Differences in tumor immune biology have been reported between Black and White women, and the tumor immune milieu could potentially drive racial differences in breast cancer etiology and outcome.

Methods: We examined the association of CD8+ cytotoxic T cells with clinical-pathological variables in the Women’s Circle of Health Study (WCHS) population of predominantly Black breast cancer patients. We evaluated 688 invasive breast tumor samples (550 Black, 138 White) using immunohistochemical staining of tissue microarray slides. CD8+ T cells were scored for each patient tumor sample with digital image analysis.

Results: Black women had a significantly higher percentage of high-grade, estrogen receptor (ER)-negative, and triple-negative tumors than White women and significantly higher CD8+ T cell density (median 87.6/mm² vs. 53.1/mm²; \(p < 0.001\)). Within the overall population and in the population of Black women only, CD8+ T cell density was significantly higher in younger patients and patients with high-grade and ER/PR-negative tumors. No significant associations were observed between CD8+ T cell density and overall survival or breast cancer-specific survival in the overall population, or when Black patients were analyzed as a separate group. However, when stratified by subtype, Black women with triple-negative breast cancer and high CD8+ T cell density showed a trend towards better overall survival in comparison with patients with low CD8+ T cell density (HR = 0.51; 95% CI 0.25 – 1.04).

Conclusions: Our data raise the possibility that distinct mechanisms of immune cell action may occur in different racial groups.

Keywords: CD8+, Breast cancer, Disparities, Immune infiltrates

Background

Breast cancer is the second leading cause of female cancer mortality in the USA [1]. Research and treatment advances have significantly lowered breast cancer mortality rates over the years. However, the decline in mortality in African American/Black women continues to lag behind. Breast cancer death rates are 41% higher in Black women than in European American/White women, with an estimated 33,840 new cases and 6540 deaths occurring in Black women in 2019 [1, 2]. The issue of racial disparities in breast cancer outcome and prognosis is a major health care challenge. The reasons underlying this
are multifactorial, including socioeconomic status, access to health care, and screening practices [3–6]. However, many studies have found that disparities persist even after adjustment for non-biological factors, and intrinsic differences in tumor biology have been reported, including a higher incidence of estrogen receptor-negative (ER−) cancer in Black women [7–11]. Moreover, recent studies have shown that African ancestry is associated with more pronounced systemic inflammatory responses than European ancestry [12–14], indicating that differences in the tumor immune milieu are also likely to exist, and this could potentially drive racial differences in breast cancer etiology and outcome.

Tumor immune response is a complex phenomenon involving multiple immune cell populations. Tumor-infiltrating lymphocytes (TILs) represent a heterogeneous population of T cells, B cells, and natural killer cells, among others, and are commonly considered the manifestation of the host antitumor immune response. T cells, particularly cytotoxic CD8+ T cells (CTLs), play a crucial role in cell-mediated antitumor immunity by targeting tumor antigen peptides for eradication [15]. Activated CD8+ T cells have a potent functional capacity, including degranulation and production of IFN-γ, which is known for its induction of tumor apoptosis and inhibition of angiogenesis [15]. CD8+ T cells have been investigated as a biomarker of the tumor immune response in many studies [16–18]. The infiltration of CTLs into the tumor microenvironment is mostly associated with a favorable prognosis in various types of solid malignancies including breast cancer, particularly the HER2-positive and triple-negative (TNBC) subtypes [16, 18]. CTLs also have been shown to predict pathological complete response to primary systemic therapy in breast cancer [19, 20] and the spatial location of CTLs has been shown to influence response to checkpoint blockade in melanoma [21]. However, many studies have shown that even when antitumor TILs such as CTLs are present, tumors continue to progress, suggesting that there are multiple negative immunoregulatory mechanisms that hinder the T cell-mediated antitumor response in the tumor microenvironment (TME) or other forms of immune escape [22, 23].

To date, there is a small but growing body of literature regarding racial differences in tumor immune responses in breast cancer [11, 24–27]. Whereas numerous prior studies have studied the role of immune cells in response to treatment and outcomes in breast cancer, the majority of these studies were conducted in populations of predominantly White women [16, 18]. Characterizations of immune cell populations are lacking in breast tumors from Black women. To address this research gap, we employed immunohistochemical (IHC) staining and quantitative digital imaging to evaluate CD8+ lymphocytes in breast tumor samples from patients enrolled in the Women’s Circle of Health Study (WCHS), a case-control study of breast cancer in Black and White women. Our purpose was to characterize and compare the density of CD8+ T cells and evaluate their prognostic value in Black women with breast cancer.

Methods
Study population
The WCHS is a multi-site, case-control study designed to evaluate the risk factors for aggressive breast cancer in Black and White women. Details on the study recruitment have been described elsewhere [28]. Briefly, participants were 20–75 years old; self-identified as Black or White; had primary, histologically confirmed invasive breast cancer or ductal carcinoma in situ (DCIS); and had no previous history of cancer other than non-melanoma skin cancer. Cases were first identified from several hospitals in New York City and then from several counties in New Jersey using rapid case ascertainment by the New Jersey State Cancer Registry (NJSCR). As part of the informed consent process, patients were asked to sign a release permitting the use of their tumor tissue blocks for research, and then tumor tissues and pathology reports were requested from treating hospitals. Clinicopathologic variables were extracted from the pathology reports: tumor size, grade, lymph node status, molecular subtype (ER, PR, and HER2 status), and whether the patient received neoadjuvant therapy. We obtained neoadjuvant chemotherapy information from the staging notation and a text search function on pathology reports. Breast cancer subtypes were inferred from ER, PR, and HER2 status information on the pathology reports and were as follows: luminal A (ER+ and/or PR+/HER2−), HER2-positive (ER+ and/or PR+/HER2+ or ER− and/or PR−/HER2+), and triple-negative (ER−/PR−/HER2−).

In this study, we used previously built tissue microarrays (TMAs) that consisted of cases only. This included 734 incident, primary invasive breast cancer cases diagnosed from 2001 to 2017. Forty-six patients who received neoadjuvant therapy were excluded, leaving 688 cases (550 Black and 138 White). The number of Black cases greatly exceeds the number of Whites, and this is due to the study design for WCHS, which focused on recruiting Black women. This study was approved by the Institutional Review Boards at Rutgers Cancer Institute of New Jersey and Roswell Park Comprehensive Cancer Center.

TMAs and immunohistochemistry
TMAs consisted of formalin-fixed paraffin-embedded (FFPE) tumor cores that were selected by a board-
certified breast pathologist (TK) based on a review of hematoxylin and eosin (H&E)-stained slides. TMA cores ranged in size from 0.6 to 1.2 mm in diameter, and most patient tumors were represented by at least two TMA cores (range 1 to 6 cores). IHC assays were performed by the Pathology Network Shared Resource (PNSR) at Roswell Park. Briefly, FFPE TMA sections were cut at 4 μm, placed on charged slides, and dried at 60°C for 1 h. The slides were cooled to room temperature, placed on the Dako Omnis autostainer, and stained with the accompanying Dako antibody and secondary reagents following the manufacturer’s recommendations. TRS High was used for epitope retrieval for 30 min, and the CD8 antibody (clone CD8/144B) was applied at 1/50 dilution. DAB (Diaminobenzidine) was applied for marker visualization. Tonsil tissue was stained in parallel as a positive control, and a negative staining control was performed by applying all staining reagents except for the primary antibody to tonsil tissue. A small number of whole sections (N = 10) that matched to cases included in the TMAs were stained using the same methods as a check for using cases in TMA format. To reduce staining variability that can occur with immunohistochemistry, we used an automated staining platform with temperature and humidity controls and clinical-grade reagents, and stained all TMAs in a single batch.

**CD8⁺ T cell digital quantification**

TMA slides were digitally scanned using Aperio ScanScope (Leica Biosystems Inc., Buffalo Grove, IL) with a ×20 bright-field microscope and then viewed using Spectrum, the accompanying web-based digital pathology system. Aperio ImageScope version 12.3.3.7014 was used to view images, create annotation layers, and circle areas of interest for analysis. The Aperio software was used to develop quantitative image analysis algorithms macros to score the IHC slides. Briefly, these algorithms used color de-convolution to distinguish DAB from the hematoxylin counterstain and provide stain separation.

Although CD8 stains the membrane compartment, the low cytoplasmic volume of T cells causes the stain to appear to cover nearly all of the cell area. Because of this, the cytoplasmic algorithm in Aperio was shown to perform better at quantifying the number of positively stained T cells; this was visually confirmed by a pathologist (WB). The cytoplasmic algorithm was fine-tuned to detect cell features and was uniformly applied to all TMA cores after our optimization and validation process. Our study pathologist visually inspected a subset of cores, especially when digital counts were high, to ensure that the high counts were reflective of the staining on the slide. Aperio reported the total number of analyzed cells, the percentage of CD8⁺ cells, and the size of the tissue area that was analyzed. In order to normalize the variable results that were produced due to the difference in tissue core sizes, the number of CD8⁺ lymphocytes in each patient sample was reported per square millimeter of tumor tissue. Nine cores lacking sufficient tumor cellularity (<50 tumor nuclei per core) were excluded from our analysis [29]. The average CD8⁺ cell density across multiple cores from each patient was used for analyses.

As many studies of tumor-infiltrating lymphocytes report on the stromal compartment, we circled the tumor areas and stromal areas in a subset of cases (N = 96) with the intention of determining if CD8 expression differs between the two regions. There was no significant difference in T cell densities between the two compartments (sign test, p = 0.337), so we did not continue manual circling because it is extremely labor-intensive.

**Outcome variables**

Data on vital status, including dates and causes of death, were available from cases who were enrolled in New Jersey through linkage with the New Jersey State Cancer Registry files. The ICD-10 code (C50) was used to identify breast cancer mortality. Follow-up time was calculated from the date of enrollment to the last contact date (censored) or date of death. Survival outcomes were available for 590 women (488 Black and 102 White), including 85 events, as of October 31, 2018. The mean follow-up time was 5.75 years (interquartile range = 3.92–9.17 years).

**Statistical analysis**

Patient demographic and clinical characteristics were summarized overall and by race using the median and interquartile range (IQR) for continuous variables, and frequencies and relative frequencies for categorical variables. CD8⁺ T cell density was evaluated in invasive primary breast tissue for 688 unique patients (N = 550 Black, N = 138 White). Separate general linear models were used to model CD8⁺ T cell density as a function of race, each clinicopathological characteristic, and their two-way interaction. F tests about the appropriate contrasts of model estimates were used to (a) evaluate, within race, the association between CD8⁺ T cell density and each characteristic and (b) compare racial groups within each level of a characteristic. For the race comparisons, Tukey’s adjustment was applied. Model assumptions were verified graphically, and a log-transformation was applied to CD8⁺ T cell density. ANCOVA analysis was conducted on the association between race and CD8⁺ T cell density, adjusting for grade, and breast cancer subtype, which were associated with both race and CD8 expression.
Overall survival (OS), defined as the time from diagnosis to the date of the last contact or of death from any cause, and breast cancer-specific survival (DSS), defined as the time from diagnosis to the date of the last contact or death from breast cancer, were summarized by race and categorized CD8+ T cell density using Kaplan-Meier methods and compared using the log-rank test. Estimates of the median and 5/10-year survival rates were obtained with 95% confidence intervals. As there are currently no established cutoff points, CD8+ T cell density was dichotomized at the cohort-specific median into low and high expression. Multivariable Cox regression models were used to evaluate the association between CD8+ T cell density and survival outcomes while adjusting for age. Additional models were explored that adjusted for grade, race, and subtype, and we also examined different cutoff points for categorizing CD8+ T cell density as high vs. low. All analyses were conducted in SAS v9.4 (Cary, NC) with a two-sided significance level of 0.05.

### Results

The demographic and clinicopathological characteristics of the study population are shown in Table 1. Consistent with other studies, Black women in the WCHS had a significantly higher percentage of high-grade, ER-negative, and triple-negative tumors than White women. There was a difference in OS, with White women having better outcomes, although it was borderline significant (HR = 0.58; 95% CI 0.33–1.03; p = 0.06). The DSS followed the same trend in this population (HR = 0.54; 95% CI 0.26–1.13; p = 0.10).

### CD8+ T cells in Black and White women

Representative staining of TMA cores is shown in Fig. 1. Black patients had a significantly higher CD8+ T cell density compared to White patients (p < 0.001), with median values of 87.6/mm² and 53.1/mm², respectively (Table 2). Higher CD8+ T cell density in tumors from Black patients was observed for all three breast cancer subtypes. The highest CD8+ T cell density was in triple-

### Table 1 Patient demographic and primary invasive tumor characteristics among cases in WCHS, 2001–2017

| Characteristic | Black | White | Overall |
|---------------|-------|-------|---------|
| Overall N     | 550 (79.9%) | 138 (20.1%) | 688 (100%) |
| Age at diagnosis Median/IQR | 55.0/(46, 62) | 52.5/(45, 60) | 54.5/(46, 61) |
| Subtype Luminal A | 322 (59.3%) | 91 (65.9%) | 413 (60.6%) |
| HER2-positive | 80 (14.7%) | 28 (20.3%) | 108 (15.9%) |
| Triple-negative | 141 (26.0%) | 19 (13.8%) | 160 (23.5%) |
| ER Positive | 366 (66.7%) | 107 (77.5%) | 473 (68.9%) |
| Negative | 183 (33.3%) | 31 (22.5%) | 214 (31.1%) |
| PR Positive | 284 (52.1%) | 82 (59.4%) | 366 (53.6%) |
| Negative | 261 (47.9%) | 56 (40.6%) | 317 (46.4%) |
| HER2 Positive | 80 (14.7%) | 28 (20.3%) | 108 (15.8%) |
| Negative | 464 (85.3%) | 110 (79.7%) | 574 (84.2%) |
| Stage I | 221 (40.2%) | 62 (45.3%) | 283 (41.2%) |
| II | 250 (45.5%) | 57 (41.6%) | 307 (44.4%) |
| III/IV | 79 (14.4%) | 18 (13.1%) | 97 (14.1%) |
| Grade Low | 69 (12.6%) | 29 (21.5%) | 98 (14.4%) |
| Intermediate | 186 (34.1%) | 60 (44.4%) | 246 (36.1%) |
| High | 291 (53.3%) | 46 (34.1%) | 337 (49.5%) |
| Tumor size < 1.0 | 54 (9.9%) | 21 (15.3%) | 75 (11.0%) |
| 1.0–1.9 | 199 (36.4%) | 54 (39.4%) | 253 (37.0%) |
| ≥ 2.0 | 294 (53.7%) | 62 (45.3%) | 356 (52.0%) |
| LN status Positive | 221 (41.2%) | 51 (37.5%) | 272 (40.4%) |
| Negative | 316 (58.8%) | 85 (62.5%) | 401 (59.6%) |
| OS 10-year rate | 0.78 | 0.87 | 0.81 |
| 95% CI | 0.72–0.84 | 0.79–0.92 | 0.76–0.85 |
| DSS 10-year rate | 0.84 | 0.92 | 0.87 |
| 95% CI | 0.78–0.89 | 0.84–0.96 | 0.82–0.90 |

ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2. Four staging categories, I–IV, from the American Joint Committee on Cancer (AJCC) were examined; stage 0 patients were not included in this study. Low tumor grade denotes well-differentiated tumors, intermediate denotes moderately differentiated, and high grade denotes poorly differentiated tumors. Tumor size (cm) was classified into three categories: < 1.0 cm, 1.0–2.0 cm, and > 2.0 cm. Lymph node (LN) status was defined as the presence (positive) or no (negative) cancer cells in the axillary lymph nodes.
negative tumors from Black patients, whereas the lowest occurred in luminal tumors from White women (Table 2). Significantly higher CD8+ T cell density in tumors from Black patients remained after adjusting for tumor grade and subtype with ANCOVA (mean difference = 156.5/mm²; 95% CI 31.1–281.9/mm²; \( p = 0.002 \)).

**Association of CD8+ T cell density with clinicopathologic characteristics**

In the overall population and Black population subset, CD8+ T cell density was noted to be significantly higher in younger patients, tumors with high grade, and tumors that were negative for ER and PR or triple-negative (Table 2, Supplemental Table 1). There was a significant interaction in which the relationship between CD8+ T cell density and disease stage depended on race (\( p = 0.04 \)); White patients had significantly lower CD8+ expression in stage I breast cancer compared to stages II and III/IV. There was no relationship between stage and CD8+ T cells in the Black population (Table 2).

**CD8+ T cell density and survival outcomes**

No significant associations were observed between CD8+ T cell density and survival outcomes in the overall population or in the Black population. However, when stratified by breast cancer subtype, we found a trend towards improved OS (HR = 0.51; 95% CI 0.25–1.03) in the Black triple-negative breast cancer patients with high CD8+ T cell density compared to those with low CD8+ density (Fig. 2a). A similar trend is seen in the overall population (HR = 0.58; 95% CI 0.29–1.13) with triple-negative breast cancer (Fig. 2b). Multivariable analysis that adjusted for age showed a trend towards improved OS in the triple-negative subset of Black patients with high CD8+ T cell density in comparison with patients with low CD8+ T cell density (HR = 0.51; 95% CI 0.25–1.04; Table 3). Additional models that also adjusted for disease grade or modified the cut-point for high/low expression did not significantly change the hazard ratio or \( p \) value associated with CD8+ T cell density. Survival analyses conducted for each tissue compartment separately (epithelial vs.

![Fig. 1](image-url) Representative CD8 immunohistochemical staining in breast tissue microarray cores. a Black participant with high CD8+ T cell density, b magnified. c Black participant with low CD8+ T cell density, d magnified. e White participant with high CD8+ T cell density, f magnified. g White participant with low CD8+ T cell density, h magnified.
stromal) were concordant with the results in which the compartments were combined (Supplemental Table 2).

### Discussion

Immunotherapy is an active and promising area of clinical oncology that has transformed patient care in some malignancies. As a result, the characterization of immune cells in the breast tumor microenvironment has received a lot of attention. Many studies have documented tumor-infiltrating lymphocytes with particular focus on CD8+ T cells in populations of White women, and several cohorts of Asian women have also been evaluated [16, 18, 19, 30]. Despite these efforts, very little is known about CD8+ tumor-infiltrating lymphocytes in Black women with breast cancer. Black patients are underrepresented in immunotherapy trials, and their unique tumor biology is mostly unaccounted for, adding to the challenge of investigating the efficacy of immunotherapeutic agents in this population [31]. In the few studies that have examined immune infiltrates in Black women with breast cancer, sample sizes were limited [11, 24–27, 32]. Our study is the first to correlate CD8+ T cell densities with tumor characteristics and clinical outcomes in a relatively large population of Black women with breast cancer.

In this study, we show that tumor-infiltrating CD8+ T cell density is significantly higher in Black breast cancer patients compared to Whites, independent of tumor subtype or grade. Our results add to an emerging trend of studies of the breast tumor microenvironment that indicates Blacks may have different tumor immune milieus than Whites. Black women have higher levels of inflammatory biomarkers and cytokines associated with breast cancer risk and survival [33–38], and genetic variants of...

### Table 2

CD8+ T cell expression (per mm^2) and patient factor interactions with race. The associations between CD8+ T cell density and clinicopathological characteristics were evaluated and stratified by race using general linear models. Racial comparisons within each factor level used Tukey-adjusted pairwise comparisons.

|                      | Blacks n | Median (IQR) | p value | Whites n | Median (IQR) | p value | Interaction p value | B vs. W within level |
|----------------------|----------|--------------|---------|----------|--------------|---------|---------------------|---------------------|
| **Total**            | 550      | 87.6 (24.9, 271.7) |         | 138      | 53.1 (14.1, 131.4) |         | < 0.001             |                     |
| **Age**              |          |              |         |          |              |         |                     |                     |
| < 40                 | 59       | 163.6 (34.7, 742.0) | 0.005   | 12       | 82.5 (16.4, 240.5) | 0.58    | 0.93                | 0.81                |
| 40–49                | 134      | 95.5 (28.6, 252.9) |         | 42       | 59.3 (24.6, 152.6) |         | 0.59                |                     |
| 50–59                | 184      | 104.3 (27.5, 279.6) |         | 48       | 45.4 (17.6, 106.3) |         | 0.13                |                     |
| 60+                  | 173      | 62.4 (16.5, 196.6) |         | 36       | 47.5 (11.8, 119.9) |         | 0.70                |                     |
| **Subtype**          |          |              |         |          |              |         |                     |                     |
| Luminal A            | 322      | 666 (224.4, 1696.6) | < 0.001 | 91       | 49.0 (13.2, 105.1) | 0.56    | 0.43                | 0.30                |
| HER2-positive        | 80       | 115.2 (33.7, 334.2) |         | 28       | 69.5 (18.6, 149.2) |         | 0.55                |                     |
| HER2-negative        | 141      | 183.1 (33.2, 838.1) |         | 19       | 56.7 (12.9, 269.3) |         | 0.14                |                     |
| **ER**               |          |              |         |          |              |         |                     |                     |
| Positive             | 366      | 70.7 (23.5, 184.4) | < 0.001 | 107      | 49.0 (13.7, 130.3) | 0.82    | 0.12                | 0.12                |
| Negative             | 183      | 155.3 (30.3, 694.5) |         | 31       | 60.9 (16.4, 152.6) |         | 0.01                |                     |
| **PR**               |          |              |         |          |              |         |                     |                     |
| Positive             | 284      | 68.2 (248, 169.3) | < 0.001 | 82       | 53.1 (19.3, 121.3) | 0.62    | 0.05                | 0.43                |
| Negative             | 261      | 135.4 (26.9, 491.3) |         | 56       | 54.7 (12.1, 157.4) |         | < 0.001             |                     |
| **HER2**             |          |              |         |          |              |         |                     |                     |
| Positive             | 80       | 115.2 (33.7, 334.2) | 0.20    | 28       | 69.5 (18.6, 149.2) | 0.41    | 0.99                | 0.35                |
| Negative             | 464      | 83.7 (243, 268.1) |         | 110      | 50.5 (13.2, 131.4) |         | 0.003               |                     |
| **Stage**            |          |              |         |          |              |         |                     |                     |
| I                    | 221      | 101.2 (27.4, 246.5) | 0.97    | 62       | 34.8 (9.8, 83.0) | 0.01    | 0.04                | < 0.001             |
| II                   | 250      | 79.9 (229, 295.8) |         | 57       | 66.1 (23.8, 166.0) |         | 0.91                |                     |
| II/IV                | 79       | 99.7 (244, 296.1) |         | 18       | 68.4 (37.5, 226.3) |         | 1.00                |                     |
| **Grade**            |          |              |         |          |              |         |                     |                     |
| Low                  | 69       | 45.2 (246, 131.0) | < 0.001 | 29       | 38.5 (9.1, 76.6) | 0.13    | 0.82                | 0.60                |
| Intermediate         | 186      | 71.9 (23.0, 162.6) |         | 60       | 45.8 (13.7, 122.2) |         | 0.63                |                     |
| High                 | 291      | 138.8 (27.1, 514.6) |         | 46       | 78.6 (246, 170.9) |         | 0.22                |                     |
| **Tumor size**       |          |              |         |          |              |         |                     |                     |
| < 1.0                | 54       | 68.8 (22.6, 235.0) | 0.30    | 21       | 60.7 (11.0, 88.4) | 0.20    | 0.19                | 0.83                |
| 1–1.9                | 199      | 105.2 (303, 321.5) |         | 54       | 45.8 (11.3, 121.3) |         | 0.004               |                     |
| ≥ 2.0                | 294      | 84.7 (216, 274.8) |         | 62       | 58.4 (20.7, 152.6) |         | 0.79                |                     |
| **LN status**        |          |              |         |          |              |         |                     |                     |
| Positive             | 221      | 85.6 (23.4, 335.5) | 0.78    | 51       | 60.9 (18.8, 152.6) | 0.43    | 0.59                | 0.22                |
| Negative             | 316      | 90.8 (25.5, 254.1) |         | 85       | 49.0 (12.9, 123.2) |         | 0.005               |                     |
cytokine-related genes of the adaptive immune response are associated with higher breast cancer risk in Black patients [39]. In genome-wide DNA methylation studies in tumors from Black and White women, the majority of differentially methylated loci by race in ER− breast cancer were related to immune signaling and immune-inflammatory pathways [40, 41]. Other reports have shown breast tumors from Black women have more prominent interferon signatures, macrophages, and higher immune dysfunction scores [11, 24–27]. A recent integrative analysis of multiple data sources from TCGA showed that breast

![Fig. 2 Kaplan-Meier plots of triple-negative breast cancer-specific survival in the WCHS population, stratified by CD8+ T cell density.](image)

**Table 3** Age-adjusted associations with survival in Black cases in WCHS

| Subtype          | CD8          | Overall survival | Disease-specific survival |
|------------------|--------------|------------------|--------------------------|
|                  | Events/N     | Hazard ratio (95% CI)* | Events/N     | Hazard ratio (95% CI)* |
| Luminal A        | High vs. low | 26/298           | 1.02 (0.47, 2.24)         | 15/298     | 0.66 (0.23, 1.94) |
| HER2-positive    | High vs. low | 11/71            | 1.36 (0.40, 4.63)         | 9/71       | 2.48 (0.55, 11.27) |
| Triple-negative  | High vs. low | 31/114           | 0.51 (0.25, 1.04)         | 23/114     | 0.58 (0.26, 1.33) |

*Hazard ratios are age-adjusted
tumor leukocyte fraction and lymphocytes were higher in women of African descent [32]. Many studies report that the effect of tumor-infiltrating CD8+ lymphocytes on the prognosis of breast cancer patients is favorable [16], with triple-negative and HER2-positive showing the highest benefit [18]. In this study, we observe a trend towards improved outcomes in triple-negative breast cancer patients with high CD8+ T cell density, although this was not statistically significant. Furthermore, no significant survival associations were otherwise noted with CD8+ T cell density in other subgroups. Since most previous work on this topic in breast cancer has been overwhelmingly focused on White or Asian patients, our data raise the possibility that distinct mechanisms of immune cell action may occur in women of African descent.

Alternatively, the lack of a significant association of CD8+ T cell density with survival in our predominantly Black population may be due to the sample size and a low number of events in the breast subtypes. Other explanations include that proximity to other immune cells may influence how CD8+ cells function in the TME, and this in turn could influence the relationship with survival in Black women. For example, CD8+ T cells may be inhibited by macrophages that may be present in higher numbers in breast tumors from Black women [25, 26], or co-occurrence with regulatory cells that we did not examine, but have been associated with poor prognosis in breast cancer [42]. Similarly, the spatial location of tissue-resident memory CD8+ T cells expressing CD103+ or the proportion of bystander CD8+ T cells may be factors [43–45]. However, our current methods preclude us from investigating cell subsets that require multiple markers to determine. Future studies will employ multispectral staining and functional analyses to more comprehensively characterize how immune subsets differ and their spatial relationships in these two racial groups.

Our findings might also be explained by immunoeediting in which there is a dynamic interplay between tumor and immune cells that leads to the eventual escape of tumor cells from the surveillance of immune cells. Studies have shown that African ancestry is associated with a stronger response to immune activation [12, 13, 46]. Yet, Blacks fare worse than Whites for many cancers [2], contrary to a wealth of studies that show a strong presence of immune cells in the TME is correlated with better pCR, prognosis, and survival [16–18]. This apparent paradox may be reconciled with the recognition that the immune system works both to constrain and promote tumor development wherein immune cells interact with the host tumor to shape tumor immunogenicity, and tumor subclones may evolve to be more evasive or immunosuppressive [47]. Because women of African descent have stronger immune responses, their own immune systems may select for tumor cells that have resistance to the surrounding immune effector cells. This could lead to higher densities of CD8+ T cells in breast tumors from Black women without the concomitant improved outcomes that are typically associated with higher levels of T cell infiltration.

The strengths of our study include the large population of Black women with breast tumor tissues available in the WCHS. We also used quantitative digital analysis of our stained tissues that served to eliminate pathologist subjectivity in scoring. Despite the advantage that TMAs provide in reducing staining variability and allowing us to screen hundreds of cases at once, the use of TMAs rather than whole sections precludes spatial analyses that could offer additional information, such as the prevalence of CD8+ T cells at the invasive margins of the tumor. It is possible that lymphocyte location rather than density may be a more prognostic marker for Black patients. However, a whole section approach is cost-prohibitive when staining hundreds of samples. Lastly, low statistical power and number of events limited our conclusions.

Conclusions
In summary, immune cell infiltrates interact with the host tumor to affect the course of the disease and may play a pivotal role in breast cancer disparities between Black and White women. A thorough evaluation of the immune landscape in breast tumors in different racial groups will inform our understanding of immune escape mechanisms, and how these may differ by ancestry, potentially providing insight for treatment strategies for Black women. Evaluating cytotoxic T cells in a large cohort of Black women is a necessary first step towards these goals. Here, we show that Blacks have significantly higher CD8+ T cell density than Whites, but this does not confer a survival advantage. Additionally, within the Black population, there was a trend towards a survival advantage with higher CD8+ T cell density only in the triple-negative subgroup. These are intriguing findings that require replication in additional populations of Black women with breast cancer. Future studies are needed to determine the functional properties of CD8+ cells in Black women and to characterize additional immune cell subtypes that may also play a role.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13058-020-01297-4.

Additional file 1: Supplemental Table 1. CD8+ T cell density in breast tumors according to clinicopathological characteristics in Black and White cases in the WCHS, 2001-2017. The associations between CD8+ T cell density and clinicopathological characteristics were evaluated in the overall cohort and stratified by race using general linear models.
Supplemental Table 2. Multivariable associations with survival for each tissue compartment (epithelial vs. stromal).

Abbreviations
CTLs: Cytotoxic CD8+ T cells; DCs: Ductal carcinoma in situ; HR: Hazard ratio; IHC: Immunohistochemistry; NJSRN: New Jersey State Cancer Registry; TILs: Tumor-infiltrating lymphocytes; TME: Tumor microenvironment; WCHS: Women’s Circle of Health Study

Authors’ contributions
The study was designed, directed, and coordinated by ARO, YA, and CBA. RPO, LS, and WB acquired the data. The analysis was done by KA, TDC, SY, GZ, RPO, LS, WB, TK, and ARO. TK and WB provided pathology assistance with image interpretation, samples, and TMA construction. YA and ARO wrote the manuscript, which was reviewed, revised, and improved by all authors. All authors read and approved the final manuscript.

Funding
This work was supported by the Breast Cancer Research Foundation, the National Center for Research Resources (S10OD019977), and the National Cancer Institute (R01 CA189943, R01 CA115135, R01 CA185623), and used Roswell Park Comprehensive Cancer Center’s Pathology Network Shared Resource and Biostatistics and Statistical Genomics Shared Resource (P30 CA016056).

Availability of data and materials
The datasets and IHC images analyzed for the current study are available from the corresponding author upon request.

Ethics approval and consent to participate
The Institutional Review Boards at Rutgers University and Roswell Park Comprehensive Cancer Center provided ethical approval for the use of patient samples in this study. All participants gave informed consent before taking part in the Women’s Circle of Health Study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 2Department of Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 3Department of Epidemiology, University of Florida, 200 Mowry Road, Gainesville, FL 32610, USA. 4Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. 5Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ, USA. 6Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA. 7Slone Epidemiology Center, Boston University Medical Campus, Boston, MA, USA. 8Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

Received: 16 January 2020 Accepted: 17 May 2020
Published online: 09 June 2020

References
1. DeSantis CE, Ma J, Goding Sauer A, Newman LA, Jemal A. Breast cancer statistics, 2017, racial disparity in mortality by state. CA Cancer J Clin. 2017;67:439–48.
2. DeSantis CE, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Cancer statistics for African Americans, 2019. CA Cancer J Clin. 2019;69:213–36.
3. Halpern MT, Bian J, Ward EM, Schrag NM, Chen AY. Insurance status and stage of cancer at diagnosis among women with breast cancer. Cancer. 2007;110:403–11.
4. Harper S, Lynch J, Meersman SC, Breen N, Davis WW, Reichman MC. Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987-2005). Cancer Epidemiol Biomark Prev. 2009;18:121–31.
5. Sprague BL, Trentham-Dietz A, Gangnon RE, et al. Socioeconomic status and survival after an invasive breast cancer diagnosis. Cancer. 2011;117:1542–51.
6. Smith SC, Ziegas A, Antos-Culver H. Delay in surgical treatment and survival after breast cancer diagnosis in young women by race/ethnicity. JAMA Surg. 2013;148:516–23.
7. Amend K, Hicks D, Ambrosone CB. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res. 2006;66:8327–30.
8. Carey LA, Perou CM, Livasy CA, et al. Race; breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:502–503.
9. Hsu D, Hu H, Rhie SK, et al. Comparison of breast cancer molecular features and survival by African and European ancestry in The Cancer Genome Atlas. JAMA Oncol. 2017;3:1654–62.
10. Keenan T, Moy B, Mroz E, et al. Comparison of the genomic landscape between primary breast cancer in African American versus white women and the Association of Racial Differences with Tumor Recurrence. J Clin Oncol. 2015;33:3621–7.
11. Martin DN, Boersma BJ, Yi M, et al. Differences in the tumor microenvironment between African-American and European-American breast cancer patients. PLoS One. 2009;4:e4531.
12. Nedelec Y, Sanz J, Baharian G, et al. Genetic ancestry and natural selection drive population differences in immune responses to pathogens. Cell. 2016;167:657–69 e21.
13. Quach H, Rotival M, Pothlichet J, et al. Genetic adaptation and Neandertal admixture shaped the immune system of human populations. Cell. 2016;167:643–56 e17.
14. Yao S, Hong CC, Ruiz-Nanavea EA, et al. Genetic ancestry and population differences in levels of inflammatory cytokines in women: role for evolutionary selection and environmental factors. PLoS Genet. 2018;14:e1007368.
15. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoeediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1–50.
16. Fridman WH, Zitvogel L, Sauves-Fridman C, Kroemer G. The immune contexture in cancer prognosis and treatment. Nat Rev Clin Oncol. 2017;14:717–34.
17. Savas P, Salgado R, Denkert C, et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol. 2016;13:228–41.
18. Ali HR, Provenzano E, Dawson SJ, et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. Ann Oncol. 2014;25:1536–43.
19. Seo AN, Lee HJ, Kim EJ, et al. Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer. Br J Cancer. 2013;109:2705–13.
20. Denkert C, von Minckwitz G, Brase JC, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. 2015;33:985–91.
21. Tumeh PC, Harvie CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:566–71.
22. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoeediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70.
23. Speiser DE, Ho PC, Verdell G. Regulatory circuits of T cell function in cancer. Nat Rev Immunol. 2016;16:599–611.
24. Carino R, Kuro-Sengul T, Miao F, et al. Macrophages as independent prognostic factors in small T1 breast cancers. Oncol Rep. 2013;29:141–8.
25. Kuro-Sengul T, Santander AM, Miao F, et al. Breast cancers from black women exhibit higher numbers of immunosuppressive macrophages with proliferative activity and of crown-like structures associated with lower survival compared to non-black Latinas and Caucasians. Breast Cancer Res Treat. 2016;158:113–26.
26. Mukhtar RA, Moore AP, Nseyo O, et al. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res Treat. 2011;130:635–44.
27. O’Meara T, Safonov A, Casadevall D, et al. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women. Breast Cancer Res Treat. 2019;175:247–59.
28. Ambrosone CB, Gupak GL, Bandera EV, et al. Conducting molecular epidemiological research in the age of HIPAA: a multi-institutional case-control study of breast cancer in African-American and European-American women. J Oncol. 2009;2009:871250.

29. Allott EH, Cohen SM, Geradts J, et al. Performance of three-biomarker immunohistochemistry for intrinsic breast cancer subtyping in the AMBER Consortium. Cancer Epidemiol Biomark Prev. 2016;25:470–8.

30. Yeong J, Lim JCT, Lee B, et al. Prognostic value of CD8 + PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. J Immunother Cancer. 2019;7:4.

31. Nazha B, Mishra M, Pentz R, Owonikoko TK. Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy. Am Soc Clin Oncol Educ Book. 2019:393–10.

32. Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48:812–30 e14.

33. Khera A, McGuire DK, Murphy SA, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005;46:464–9.

34. Carroll JF, Fulda KG, Chiapa AL, et al. Impact of race/ethnicity on the relationship between visceral fat and inflammatory biomarkers. Obesity (Silver Spring). 2009;17:1420–7.

35. Heikkila K, Harris R, Lowe G, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis. Cancer Causes Control. 2009;20:15–26.

36. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27:3437–44.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.